Staying a step ahead of disease causing bacteria that can become resistant to antibiotics
Main Category: MRSA / Drug ResistanceArticle Date: 04 Nov 2005 - 0:00 PDT
| Patient / Public: | ![]() |
2.33 (3 votes) |
| Healthcare Prof: | ![]() |
4.5 (2 votes) |
A new study of genetic changes in bacteria may ultimately help drug makers stay a step ahead of disease-causing bacteria that can become resistant to antibiotics.
The secret lies in understanding the function of the ribosome, a tiny protein-making factory residing inside most cells.
Many currently used antibiotics alter a ribosome's ability to make proteins, said Kurt Fredrick, a study co-author and an assistant professor of microbiology at Ohio State University.
But he and his colleagues at the University of Illinois thought that there may be additional places in a ribosome that future antibiotics could affect, places that current antibiotics don't currently target.
The researchers were right.
"Antibiotic resistance will always be an issue," Fredrick said. "But as long as we can stay ahead of the ability of the pathogens to resist antibiotics, we're okay."
The findings appear online this week in the Early Edition of the Proceedings of the National Academy of Sciences. Fredrick co-authored the study with lead author Alexander Mankin and with Aymen Yassin, both with the University of Illinois at Chicago.
Fredrick provided a strain of Escherichia coli important for the study.
In order to find out if their initial hunch was correct - that there actually are other "hot spots" on a ribosome that could act as potential targets for antibiotics - the researchers first introduced a mutated copy of the ribosomal genes into E. coli cells and looked for those rare mutations that could interfere with cell growth. It was known from previous studies that such deleterious mutations occurred within critical regions of the ribosome.
After identifying dozens of deleterious mutations, the researchers were able to produce a composite map showing where these mutations were positioned on the ribosomes. Interestingly, the map indicated that there were four additional places on ribosomes where these mutations clustered. While researchers already knew that these sites existed, they did not know that these areas could possibly become targets for antibiotics.
These sites are what may one day give pharmaceutical companies an edge in creating new antibiotics in order to keep ahead of bacteria's clever way of developing resistance to antibiotics.
"Now that we know these other sites exist and that they could be potential targets for antibiotics, the next step is to figure out how exactly these mutations interfere with the cell's own ribosomes," Fredrick said.
The research was supported by a grant from the National Institutes of Health.
Kurt Fredrick
fredrick.5@osu.edu
Ohio State University
http://researchnews.osu.edu
Visit our mrsa / drug resistance section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/32897.php>
APA
http://www.medicalnewstoday.com/releases/32897.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




